The most instructive number in the Christopher Harwood case isn’t the $46 million headline figure — it’s the roughly $28 million gap between what his company billed and what Medicare actually paid, a gap that reveals exactly how federal fraud enforcement measures harm and why health care fraud schemes can run for years before anyone notices.
Key Points
- Christopher Harwood, 44, owner of Fort Lauderdale telemedicine company TelevisitMD, pleaded guilty to conspiracy to commit health care fraud and wire fraud and was sentenced to 20 years in federal prison.
- Federal prosecutors documented at least $46.2 million in false and fraudulent Medicare claims for durable medical equipment and laboratory testing submitted over a scheme spanning more than six years.
- Medicare actually paid approximately $17.9 million of those claims — the figure a federal judge ordered Harwood to repay as restitution, alongside forfeiture of $10,431,463.
- The scheme relied on a now-familiar telehealth fraud architecture: aggressive telemarketing to Medicare beneficiaries, paired with physicians who approved orthotic braces and genetic tests without adequate examination.
- The case sits inside a broader, well-documented national pattern of telemedicine-enabled Medicare fraud that federal watchdogs have flagged repeatedly as an ongoing program-integrity risk.
What Happened
Harwood built TelevisitMD as a telemedicine outfit, but prosecutors say its real function was to manufacture paperwork. According to the Southern District of Florida indictment, Harwood and his co-conspirators submitted at least $46.2 million in false and fraudulent claims to Medicare for durable medical equipment and laboratory tests over more than six years. He pleaded guilty to conspiracy to commit health care fraud and wire fraud, and on October 23, 2026, a federal court sentenced him to 20 years in prison — a term long enough to signal that the Department of Justice and the sentencing judge treated this as a serious, sustained criminal enterprise rather than an isolated billing error.
The court also ordered Harwood to pay $17,942,402 in restitution to Medicare and to forfeit $10,431,463 in ill-gotten proceeds. Those figures matter because they anchor the case in adjudicated fact, not just accusation: a guilty plea is a formal admission of criminal conduct, and a restitution order reflects a judge’s determination of actual program loss, not merely what prosecutors alleged at the charging stage.
How the Scheme Worked
The mechanism described in court filings follows a pattern that has become depressingly familiar to Medicare fraud investigators. Telemarketers identified and contacted Medicare beneficiaries — often elderly patients — and steered them toward orthotic braces and genetic testing kits they had not sought out and, in many cases, did not need. Physicians connected to the operation then approved the orders, in some instances without conducting the kind of examination that would normally justify a prescription for a knee brace or a genetic cancer-screening panel. The indictment alleges the goods and services were “medically unnecessary” and “obtained through illegal kickbacks and bribes,” rendering them ineligible for Medicare reimbursement from the outset.
From Allegation to Admission: Reading the Numbers Correctly
One distinction deserves more attention than headlines typically give it: the $46.2 million figure represents claims submitted to Medicare, while the $17.9 million restitution figure represents what the program actually paid out before the scheme was stopped. Both numbers are real and both matter, but they measure different things — one is the scale of the attempted fraud, the other is the scale of the realized theft. Conflating them risks overstating taxpayer loss even as it understates the audacity of the scheme itself, since Harwood’s operation attempted to extract more than twice what it ultimately collected. Medicare’s claims-processing system caught or denied a meaningful share of the submitted billings, which is itself a data point about where program safeguards worked and where they didn’t.
A Familiar Playbook: Telehealth Fraud as a National Pattern
Harwood’s conviction is not an outlier; it’s a data point in a well-established trend. The Department of Health and Human Services’ Office of Inspector General has flagged telehealth oversight as a persistent program-integrity concern, warning that Medicare’s rapid expansion of remote-care billing created openings for exactly this kind of arrangement — a marketer, a distant clinician, a supplier, and a claims pipeline with limited friction. The Justice Department has pursued a string of comparable cases in recent years, including telemedicine operators sentenced for schemes reaching well beyond $100 million in fraudulent billing, underscoring that the core vulnerability is structural rather than unique to any single defendant.
What makes telehealth-adjacent fraud especially durable is the same thing that makes legitimate telemedicine valuable: distance. A beneficiary in one state can be “examined” by a clinician in another, licensed and credentialed on paper but never conducting the kind of hands-on assessment that would surface a mismatch between the patient’s actual condition and the device or test being ordered. Medicare’s claims system, built to pay promptly and audit after the fact, assumes good faith on the front end — an assumption fraud schemes are specifically engineered to exploit before investigators catch up.
What the Sentence Signals Going Forward
A 20-year sentence, full restitution, and asset forfeiture together represent one of the more severe outcomes in recent telemedicine fraud prosecutions, and they reflect a judicial finding that Harwood organized and led the conspiracy rather than merely participating in it. For an industry still expanding rapidly — telehealth billing has grown substantially across Medicare, TRICARE, and the Federal Employees Health Benefits Program since the pandemic-era rule changes that loosened in-person requirements — the case functions as a warning shot to operators tempted to treat virtual visits as a rubber stamp. It also reinforces a point regulators have made consistently: the fraud risk in telemedicine rarely lives in the technology itself, but in the absence of a genuine clinical relationship behind the screen.
🚨FRAUDSTER SENTENCED🚨
A telemedicine company owner was sentenced to 20 years in prison for leading a Medicare fraud scheme that stole $46.2 million over more than six years.
Christopher Harwood owned TelevisitMD.
He and others used aggressive telemarketing to push…
— Breanna Morello (@BreannaMorello) October 23, 2026
The Bottom Line
Harwood’s case closes with a conviction, a lengthy sentence, and a restitution order that puts a precise dollar figure on the harm to the Medicare trust fund. The larger lesson outlasts the case file: telehealth’s convenience and its fraud exposure are two sides of the same structural coin, and taxpayers bear the cost whenever the clinical relationship at the center of a billed service turns out to be fictional.
